Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K2 | P36507 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 13/20 | 0.35 |
| ▸ | KDM5A | P29375 | 2/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.35 |
| ▸ | GPR6 | P46095 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1919943 | 0.91 | BRD4 (0.36) | MAP2K2MAP2K1BRD4CREBBPKDM4C | |
| SCHEMBL13015132 | 0.86 | MAP2K1 (0.45) | MAP2K2MAP2K1 | |
| SCHEMBL1921116 | 0.86 | MAP2K1 (0.43) | MAP2K2MAP2K1 | |
| SCHEMBL1920512 | 0.86 | MAP2K1 (0.47) | MAP2K2MAP2K1 | |
| SCHEMBL12533858 | 0.85 | MAP2K1 (0.50) | MAP2K2MAP2K1 | |
| SCHEMBL1921206 | 0.82 | MAP2K1 (0.38) | MAP2K2MAP2K1 | |
| SCHEMBL1920476 | 0.78 | MAP2K1 (0.43) | MAP2K2MAP2K1BRD4CREBBP | |
| SCHEMBL1920639 | 0.77 | BRD4 (0.36) | MAP2K1BRD4CREBBPKDM4CKDM5A | |
| SCHEMBL1920655 | 0.76 | DHODH (0.38) | KDM4C | |
| SCHEMBL12534001 | 0.74 | MAP2K1 (0.48) | MAP2K2MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855216-B2 | Aza-indolyl compounds and methods of use | GENENTECH, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| EP-2099796-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2008-10-02 | — | — | US | disclosed |
| WO-2008067481-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | CDKN1A, MKI67, CCNI | MAP2K2 16/4885MAP2K1 24/4885BRD4 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.